7 results
Warm Antibody Autoimmune Hemolytic Anemia 
1) DIAGNOSE AIHA
 • Anemia: macrocytic > normocytic, ↑ reticulocytes
 •
Warm Antibody Autoimmune ... Hemolytic Anemia 1) DIAGNOSE ... 2) LOOK FOR a cause ... #management #treatment ... #rheumatology
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
(SLE) - Diagnosis ... Manifestations: Malar ... Positive in 60-80% of cases ... life-threatening • Treatment ... #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
& NPSLE rare, Malar ... Manifestations: Malar ... Usual therapeutic management ... comparison #table #rheumatology ... #diagnosis #management
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
autoantibodies that will cause ... permeability Diagnosis ... CNS #neurology #rheumatology ... #cerebritis #diagnosis ... #management #treatment
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
Leishmaniosis, malaria ... Drugs, Unknown cause ... Treatment: • ... #management #treatment ... #summary #rheumatology
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
& NPSLE rare, Malar ... Discontinuation of causal ... #DIL #rheumatology ... #diagnosis #treatment ... #management
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
Muscle atrophy may cause ... levels • NXP-2 antibody ... positive patients Treatment ... Dermatomyositis #diagnosis ... #management #rheumatology